Fezakinumab

Drug Profile

Fezakinumab

Alternative Names: ILV-094; PF-5212367

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Pfizer
  • Class Antirheumatics; Monoclonal antibodies; Recombinant proteins
  • Mechanism of Action Interleukin-22 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Psoriasis; Rheumatoid arthritis

Most Recent Events

  • 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Canada (IV)
  • 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Canada (SC)
  • 11 Aug 2011 Discontinued - Phase-I for Psoriasis in Hong Kong (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top